K

Serial Number 97204204
733

Registration Progress

Application Filed
Jan 5, 2022
Under Examination
Jul 25, 2023
Approved for Publication
May 30, 2023
Published for Opposition
May 30, 2023
Registered

Attorney Assistance

Statement of Use Due - Extension 4 Granted
Due: Jan 25, 2026 180 days

Trademark Image

K

Basic Information

Serial Number
97204204
Filing Date
January 5, 2022
Published for Opposition
May 30, 2023
Drawing Code
3

Status Summary

Current Status
Active
Status Code
733
Status Date
Jul 21, 2025
Application
Pending
Classes
005 042

Rights Holder

Kymera Therapeutics, Inc.

03
Address
500 North Beacon Street, 4th Floor
Watertown, MA 02472

Ownership History

Kymera Therapeutics, Inc.

Original Applicant
03
Watertown, MA

Kymera Therapeutics, Inc.

Owner at Publication
03
Watertown, MA

Legal Representation

Attorney
Lisa M. Tittemore

USPTO Deadlines

Next Deadline
180 days remaining
Statement of Use Due - Extension 4 Granted
Due Date
January 25, 2026
Extension Available
Until July 25, 2024

Application History

41 events
Date Code Type Description Documents
Jul 22, 2025 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Jul 21, 2025 EX4G S SOU EXTENSION 4 GRANTED Loading...
Jul 21, 2025 EXT4 S SOU EXTENSION 4 FILED Loading...
Jul 21, 2025 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Jun 6, 2025 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
Jun 6, 2025 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
Jun 6, 2025 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
Mar 4, 2025 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Jan 25, 2025 EX3G S SOU EXTENSION 3 GRANTED Loading...
Jan 24, 2025 EXT3 S SOU EXTENSION 3 FILED Loading...
Jan 24, 2025 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Jul 24, 2024 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Jul 18, 2024 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Jul 18, 2024 EX2G S SOU EXTENSION 2 GRANTED Loading...
Jul 18, 2024 EXT2 S SOU EXTENSION 2 FILED Loading...
Jun 26, 2024 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
Jun 26, 2024 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
Jun 26, 2024 CHAN I APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Loading...
Jun 26, 2024 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
Jun 26, 2024 EWAF I TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS Loading...
Jun 26, 2024 COAR I TEAS CHANGE OF OWNER ADDRESS RECEIVED Loading...
Jan 24, 2024 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Jan 22, 2024 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Jan 22, 2024 EX1G S SOU EXTENSION 1 GRANTED Loading...
Jan 22, 2024 EXT1 S SOU EXTENSION 1 FILED Loading...
Jul 25, 2023 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
May 30, 2023 PUBO A PUBLISHED FOR OPPOSITION Loading...
May 30, 2023 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
May 10, 2023 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Apr 22, 2023 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Apr 12, 2023 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Apr 11, 2023 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Apr 11, 2023 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Nov 21, 2022 DOCK D ASSIGNED TO EXAMINER Loading...
Oct 11, 2022 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Oct 11, 2022 GNRT F NON-FINAL ACTION E-MAILED Loading...
Oct 11, 2022 CNRT R NON-FINAL ACTION WRITTEN Loading...
Oct 11, 2022 DOCK D ASSIGNED TO EXAMINER Loading...
Jan 11, 2022 MDSC E NOTICE OF DESIGN SEARCH CODE E-MAILED Loading...
Jan 10, 2022 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Jan 8, 2022 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceutical and medical preparations for the treatment of cancer, immune inflammatory diseases, and autoimmune diseases; Pharmaceutical therapeutics for the treatment of cancer, immune inflammatory diseases, and autoimmune diseases
Class 042
Research and development of therapeutic drugs for the treatment of cancer, immune inflammatory diseases, and autoimmune diseases; Research and development of therapeutic antibodies and pharmaceuticals; Research and development of technology in the field of therapeutic antibodies, pharmaceuticals and biopharmaceuticals; Development of pharmaceutical preparations and medicines; Pharmaceutical drug development services and drug discovery services; Medical research for development of therapeutic modalities for treatment of diseases; Custom design and development of biochemical assays and chemical reagents for use in scientific and biomedical research; Clinical studies, namely, clinical research in the field of oncology, immune oncology, and autoimmune diseases; Preclinical and clinical development of therapeutic products being pharmaceutical preparations and medicines

Additional Information

Design Mark
The mark consists of two four-sided polygons above a downward-facing letter "K", where the two polygons form the eyes of an animal's face and the letter "K" forms the nose and mouth of an animal's face.
Color Claim
Color is not claimed as a feature of the mark.

Classification

International Classes
005 042